0001104659-21-110525.txt : 20210827
0001104659-21-110525.hdr.sgml : 20210827
20210827160943
ACCESSION NUMBER: 0001104659-21-110525
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210826
FILED AS OF DATE: 20210827
DATE AS OF CHANGE: 20210827
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Prichard Heather Ledbetter
CENTRAL INDEX KEY: 0001877712
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39532
FILM NUMBER: 211218996
MAIL ADDRESS:
STREET 1: 820 BROWNWICH STREET
CITY: WAKE FOREST
STATE: NC
ZIP: 27587
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Humacyte, Inc.
CENTRAL INDEX KEY: 0001818382
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 851763759
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54
CITY: DURHAM
STATE: NC
ZIP: 27713
BUSINESS PHONE: 919-313-9633
MAIL ADDRESS:
STREET 1: 2525 EAST NORTH CAROLINA HIGHWAY 54
CITY: DURHAM
STATE: NC
ZIP: 27713
FORMER COMPANY:
FORMER CONFORMED NAME: Alpha Healthcare Acquisition Corp.
DATE OF NAME CHANGE: 20200716
4
1
tm2125954-16_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-08-26
0
0001818382
Humacyte, Inc.
HUMA
0001877712
Prichard Heather Ledbetter
2525 EAST NORTH CAROLINA HIGHWAY 54
DURHAM
NC
27713
0
1
0
0
Chief Operating Officer
Common Stock
2021-08-26
4
A
0
2625
A
2625
D
Stock Options (right to buy)
1.15
2021-08-26
4
A
0
6564
A
2022-12-14
Common Stock
6564
6564
D
Stock Options (right to buy)
1.19
2021-08-26
4
A
0
78779
A
2023-11-22
Common Stock
78779
78779
D
Stock Options (right to buy)
2.56
2021-08-26
4
A
0
78779
A
2025-12-11
Common Stock
78779
78779
D
Stock Options (right to buy)
6.54
2021-08-26
4
A
0
157558
A
2028-04-12
Common Stock
157558
157558
D
Stock Options (right to buy)
10.28
2021-08-26
4
A
0
1575
A
2021-12-14
2030-12-14
Common Stock
1575
1575
D
On August 26, 2021 , Alpha Health care Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub" ) and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each share of Legacy Humacyte stock was exchanged for 0.2626 shares of common stock of Humacyte, Inc.
Options are fully vested and exercisable.
As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.
Options to purchase 2,625 shares of Common Stock granted on 12/14/2020, which vest as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Accordingly, columns 5, 7, and 9 of Table II report the number of securities equal to three-fifths of the 12/14/2020 option grant.
/s/ Heather Ledbetter Prichard by Dale A. Sander as Attorney-in-Fact
2021-08-27